Zacks Research Has Bullish Outlook for PLX FY2026 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Zacks Research lifted their FY2026 EPS estimates for Protalix BioTherapeutics in a research report issued on Wednesday, March 18th. Zacks Research analyst J. Vandermosten now anticipates that the company will earn $0.17 per share for the year, up from their previous estimate of ($0.06). The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Protalix BioTherapeutics’ FY2027 earnings at $0.00 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Protalix BioTherapeutics in a research report on Thursday, March 19th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Protalix BioTherapeutics currently has a consensus rating of “Buy” and an average price target of $12.00.

Protalix BioTherapeutics Stock Performance

Shares of PLX stock opened at $2.07 on Monday. The firm has a market cap of $166.78 million, a price-to-earnings ratio of -15.92 and a beta of -0.26. Protalix BioTherapeutics has a 52 week low of $1.32 and a 52 week high of $3.19. The firm’s 50-day simple moving average is $2.61 and its two-hundred day simple moving average is $2.21.

Institutional Trading of Protalix BioTherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. R Squared Ltd bought a new stake in shares of Protalix BioTherapeutics during the 4th quarter valued at $26,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Protalix BioTherapeutics during the 2nd quarter valued at about $27,000. SG Americas Securities LLC purchased a new position in Protalix BioTherapeutics during the 4th quarter valued at about $31,000. Bank of America Corp DE increased its position in shares of Protalix BioTherapeutics by 364,766.7% during the second quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock valued at $32,000 after buying an additional 21,886 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Protalix BioTherapeutics in the fourth quarter worth about $34,000. 16.53% of the stock is currently owned by institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.